Digital Platform for MGC Pharma's International Library of Cannabinoids with RMIT

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), a European based 'Seed to Pharmacy' bio-pharma company focused on developing and commercialising cannabinoid derived medicines, is pleased to announce that it has completed the initial critical development phase of the International Library of Cannabinoids ('ILC') digital platform that it is developing in tandem with leading Australian research university, Royal Melbourne Institute of Technology ('RMIT'). The ILC digital platform will provide an interface connecting doctors and patients with clinical research and information on cannabinoid sequences and their potential treatments.

Overview:

- MGC Pharma and RMIT are jointly developing the International Library of Cannabinoids – a world first centralised platform compiling the diverse range of existing data on the therapeutic benefits of cannabinoids
- The ILC will collect MGC's proprietary data in addition to data from diverse clinical studies, academic publications and patient feedback, as well as data on diverse cannabinoid strains
- Collected and analysed data from the ILC will assist and enhance the work of doctors and researchers, and improve efficacy estimates of cannabinoids in the treatment of various diseases
- The ILC platform facilitates increased understanding for doctors of cannabinoid treatments which could translate to an increase in prescriptions and application of cannabinoid-based products, including MGC's products
- The ILC favourably mentioned in an academic paper titled Automated Gathering and Analysis of Cannabinoids Treatment Data published in the Journal of Procedia Computer Science ('the Paper')
- The Paper outlines how the ILC could be utilised for the design and implementation of clinical trials via its mobile and web-based applications

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "The completion of the first development stage for the digital interface, based on the ILC, is a significant milestone in the products development. The ILC platform has the potential to be the Google of medicinal cannabis. With both web and mobile interfaces, it will be a readily accessible, centralised source on clinical data on phytocannabinoids including mass data and statistical results. Potentially industry changing, it is hoped that the ILC platform will increase doctors' understanding of the potential usages of cannabinoid based medicinal products thus leading to increased adoption, potentially improved patient experience and heightened demand for products, including MGC's offering including epilepsy focussed CannEpil™ and dementia focussed CogniCann™.

"The Board of MGC Pharma recognised at an early stage that being at the forefront of scientific and clinical developments in the medicinal cannabis industry was integral to becoming a leading medicinal cannabis pharma company. The ILC is an excellent example of this, and as such I am delighted that it has also received international recognition in the Journal of Procedia Computer Science.

info@mgcpharma.com.au | mgcpharma.com.au
MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth, WA 6005
PO Box 1976, West Perth WA 6872
T: +61 8 6382 3390

1
-
3

"We are advancing our seed-to-pharmacy strategy at pace, and as such this is a time of rapid progress. I look forward to providing shareholders with further regular updates of key developments in due course."

Nitin Mantri, Associate Professor in Biotechnology at RMIT, commented, "We have produced the ILC database that can collect comprehensive information about strains (including genetics, grow conditions and chemical profile) and clinical trials (including details of diseases and follow up treatments). This data will over time benefit doctors and industry to choose the right strain for treating a specific disorder."

In August 2017, the Company signed a binding Umbrella Agreement with leading Australian research university, the Royal Melbourne Institute of Technology, to collaborate exclusively on medicinal cannabis research initiatives in Australia. The agreement included MGC Pharma partially funding a state-of-the-art cultivation, extraction and research facility within RMIT, building upon the Company's medicinal cannabis IP and results from its leading global research programs. As part of the Umbrella Agreement, RMIT agreed to dedicate the facility and additional laboratories to the project for a minimum period of 5 years.

This agreement consists of two key initial projects:
1. Establish a world first library of cannabis medicine where details on medicinal cannabis clinical research, cannabinoid sequences and their treatments can be found – the International Library of Cannabinoids
2. Investigate the positive effects of medicinal cannabis derived formulations on several types of cancer and cancer side effects. The cancer research program will initially focus on melanoma treatment, beginning with pre-clinical trials

The International Library of Cannabinoids platform, including Strain, Research and Clinical data, provides:
- Structured database
- Web interface
- Search tools for doctors and researchers
- App for patients to enter regular data
- Integration of global knowledge and global data

The ILC's potential has been recognised in a paper titled *Automated Gathering and Analysis of Cannabinoids Treatment Data,* published in the Journal of Procedia Computer Science, which outlines the strategic benefits of the ILC platform.

The Paper presents the International Library of Cannabinoids as an open source platform to integrate and analyse the cannabinoids research data gathered from academic publications, industrial and clinical trials as well as patients. The ILC focuses on the analysis of the usability aspects important for the applications collecting the treatment data as well as data on diverse cannabinoid strains. The collected data will then be used to estimate the efficacy of cannabinoid treatments of various disorders, which will provide evidence-based assistance for doctors, researchers and industry to identify the right cannabinoid profiles for various conditions.

The Paper is available now on the MGC Pharma Company website and can be accessed using the following link: https://mgcpharma.com.au/wp-content/uploads/2019/06/Paper.pdf

--Ends--

For further information, please contact:

Media Enquiries	**UK IR/Media Advisors**	**MGC Pharmaceuticals Ltd**
Justin Kelly	Gaby Jenner/ Catherine Leftley	Brett Mitchell
Media and Capital Partners	St Brides Partners Ltd	Executive Chairman
+61 408 215 858	+44 (0) 207 236 1177	+61 8 6382 3390
justin.kelly@mcpartners.com.au	gaby@stbridespartners.co.uk	info@mgcpharma.com.au
	catherine@stbridespartners.co.uk	

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is an EU-based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality cannabinoids-based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels